3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors

US11091490B2 · kind B2 · utility

Assignees

• Medizinische Universität Innsbruck · AT
• Vichem Chemie Kutató Korlátolt Felelösségü Társaság · HU

Inventors

• Winfried Wunderlech · Bovenden, DE
• Lukas A. Huber · Schwaz, AT
• Johann Leban · Planegg, DE
• Janos Pato · Budapest, HU
• Laszlo Orfi · Budapest, HU
• Wáczek Frigyes · Budapest, HU
• Péter Bánhegyi · Budapest, HU
• Anna Sípos · Dunakeszi, HU
• Csaba Szántai-kis · Budapest, HU

Key dates

• Filing date: Nov 29, 2017
• Grant date: Aug 17, 2021
• Expiry date: Nov 29, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/0053
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to 3-amino-pyrazolo[3,4-d]pyrimidin-4-ones, such as for example, N-{4-[1-(2,6-dichloro-4-sulfamoyl-phenyl)-3-dimethylamino-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl]-phenyl}-2-diethylamino-acetamide, particularly useful as cyclin dependent kinase (CDK) inhibitors, pharmaceutical compositions comprising the same and the use thereof in particular in the prophylaxis and/or treatment of cancer and other proliferative diseases. Furthermore, the present invention relates to processes for the synthesis of said 3-aminopyrazolo[3,4d]pyrimidin-4-ones and intermediates to be used in the processes of the present invention.